Equities

OS Therapies Inc

OS Therapies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.86
  • Today's Change0.132 / 7.64%
  • Shares traded38.53k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-7.42m
  • Incorporated2018
  • Employees4.00
  • Location
    OS Therapies Inc15825 Shady Grove Road, Suite 135ROCKVILLE 20850United StatesUSA
  • Phone+1 (410) 297-7793
  • Fax+1 (302) 655-5049
  • Websitehttps://ostherapies.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Carisma Therapeutics Inc20.27m-63.80m35.40m107.00------1.75-1.56-1.560.4927-0.26650.2723----189,420.60-85.73-30.87-101.81-34.47-----314.78-255.66---------62.70---336.93--255.27--
Elevation Oncology Inc0.00-41.95m35.78m29.00--0.5159-----0.807-0.8070.001.170.00----0.00-40.67---43.53-------------375.060.309------51.93------
NextCure Inc0.00-58.52m36.13m82.00--0.4774-----2.09-2.090.002.700.00----0.00-50.82-22.59-54.42-23.54-------964.96----0.00------16.07---23.17--
CERo Therapeutics Holdings Inc0.00-2.54m36.58m8.00---------0.3796-0.37960.00-0.92260.00----0.00-9.96---33.80-----------------------279.82------
Rapt Therapeutics Inc0.00-107.49m36.65m70.00--0.3837-----2.78-2.780.002.740.00----0.00-69.76-46.30-77.90-49.97-------3,522.72----0.00---100.00---39.31---20.31--
AN2 Therapeutics Inc0.00-60.70m36.75m41.00--0.419-----2.04-2.040.002.940.00----0.00-48.27---53.56--------------0.00-------51.33------
Intensity Therapeutics Inc0.00-16.26m37.18m5.00--13.47-----1.18-1.180.000.20050.00----0.00-147.61---171.25--------------0.00-------56.45------
OS Therapies Inc0.00-7.42m37.23m4.00---------0.3566-0.35660.00-0.03340.00----0.00-559.23-----------------2.13---------24.09------
Lumos Pharma Inc2.21m-34.92m37.45m30.00--7.62--16.98-4.29-4.290.27050.56820.0676--12.7566,818.18-107.08-29.78-132.78-32.32-----1,583.49-2,937.61----0.00--34.67-30.31-9.57------
Calidi Biotherapeutics Inc0.00-27.95m37.66m41.00---------5.61-5.610.00-1.100.00----0.00-208.29---2,279.15-------------28.13-----100.00---14.90------
FibroGen Inc180.01m-121.79m38.88m486.00------0.216-1.23-1.231.81-2.420.49671.297.49370,399.20-34.51-30.62-103.81-42.3176.8793.52-69.48-119.081.16-7.70----4.99-7.053.21---20.67--
Anebulo Pharmaceuticals Inc0.00-7.92m38.90m2.00--20.49-----0.306-0.3060.000.07320.00----0.00-137.58---154.87--------------0.00------30.09------
LAVA Therapeutics NV7.40m-24.18m38.91m37.00--0.9077--5.26-0.8976-0.89760.27411.630.0689--3.23199,946.00-22.51---27.11--97.78---326.89------0.1257---65.09---31.55------
Iterum Therapeutics PLC0.00-30.55m40.19m14.00---------2.00-2.000.00-0.50680.00----0.00-109.80-118.12-297.32-199.23-------890,554.10---7.382.05------13.64---32.09--
Data as of Nov 22 2024. Currency figures normalised to OS Therapies Inc's reporting currency: US Dollar USD

Institutional shareholders

0.72%Per cent of shares held by top holders
HolderShares% Held
Millennium Management LLCas of 30 Sep 202460.44k0.29%
CM Management LLCas of 30 Sep 202450.00k0.24%
Delta Investment Management LLCas of 30 Sep 202418.08k0.09%
HRT Financial LP (US)as of 30 Sep 202417.58k0.08%
UBS Securities LLCas of 30 Sep 20243.81k0.02%
Armstrong Advisory Group, Inc.as of 30 Sep 2024100.000.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.